Payment overview · 2025
General Payments
$408.19
21 reported records · 15 companies
Healthcare provider profile · identity verified
Michael James, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · RALEIGH, NC · NPI 1538161609
Verified facts
What the public records show
CMS Open Payments records show Michael James, M.D. received $408.19 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 12.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Nuplazid, Otezla, Ozempic.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nuplazid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1079 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1079 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.38 | 12.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.13 | 11.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.91 | 11.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.22 | 8.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.49 | 7.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $28.22 | 6.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.41 | 6.0% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $20.88 | 5.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$20.67 | 5.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.05 | 4.7% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $18.49 | 4.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.61 | 4.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.37 | 4.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.43 | 3.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.93 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $408.19 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.13 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $45.91 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $36.22 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.08 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $29.93 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $28.22 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| VELSIPITY Normalized: velsipity |
Drug | PFIZER INC. | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1079 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 26 | exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 96 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1079 | 160 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
212 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
96 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
42 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1079 | 160 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 32 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1173 | 263 |
| Amlodipine Besylate | Amlodipine Besylate | 1150 | 235 |
| Eliquis | Apixaban | 1079 | 160 |
| Gabapentin | Gabapentin | 1064 | 171 |
| Levothyroxine Sodium | Levothyroxine Sodium | 975 | 188 |
| Furosemide | Furosemide | 796 | 170 |
| Trazodone Hcl | Trazodone Hcl | 648 | 123 |
| Pantoprazole Sodium | Pantoprazole Sodium | 539 | 123 |
| Losartan Potassium | Losartan Potassium | 500 | 133 |
| Lisinopril | Lisinopril | 495 | 120 |
| Pravastatin Sodium | Pravastatin Sodium | 492 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 489 | 126 |
| Metoprolol Tartrate | Metoprolol Tartrate | 480 | 91 |
| Tamsulosin Hcl | Tamsulosin Hcl | 466 | 121 |
| Carvedilol | Carvedilol | 442 | 87 |
| Escitalopram Oxalate | Escitalopram Oxalate | 434 | 68 |
| Omeprazole | Omeprazole | 430 | 115 |
| Metformin Hcl | Metformin Hcl | 388 | 72 |
| Potassium Chloride | Potassium Chloride | 388 | 78 |
| Mirtazapine | Mirtazapine | 382 | 89 |
| Sertraline Hcl | Sertraline Hcl | 372 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 369 | 100 |
| Donepezil Hcl | Donepezil Hcl | 347 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 317 | 72 |
| Duloxetine Hcl | Duloxetine Hcl | 304 | 71 |
| Valsartan | Valsartan | 299 | 25 |
| Alprazolam | Alprazolam | 293 | 63 |
| Allopurinol | Allopurinol | 270 | 59 |
| Quetiapine Fumarate | Quetiapine Fumarate | 270 | 44 |
| Spironolactone | Spironolactone | 267 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 251 | 61 |
| Jardiance | Empagliflozin | 251 | 48 |
| Levetiracetam | Levetiracetam | 233 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 222 | 46 |
| Xarelto | Rivaroxaban | 212 | 30 |
| Humalog Kwikpen U-100 | Insulin Lispro | 196 | 40 |
| Tramadol Hcl | Tramadol Hcl | 196 | 72 |
| Myrbetriq | Mirabegron | 188 | 16 |
| Famotidine | Famotidine | 181 | 44 |
| Simvastatin | Simvastatin | 173 | 41 |
| Latanoprost | Latanoprost | 172 | 55 |
| Prednisone | Prednisone | 169 | 63 |
| Ezetimibe | Ezetimibe | 166 | 36 |
| Finasteride | Finasteride | 166 | 37 |
| Telmisartan | Telmisartan | 165 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 163 | 47 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 157 | 36 |
| Aripiprazole | Aripiprazole | 154 | 18 |
| Memantine Hcl | Memantine Hcl | 151 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 147 | 37 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 138 | 23 |
| Warfarin Sodium | Warfarin Sodium | 132 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 74 |
| Lorazepam | Lorazepam | 130 | 70 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 128 | 30 |
| Midodrine Hcl | Midodrine Hcl | 127 | 32 |
| Oxycodone Hcl | Oxycodone Hcl | 126 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 50 |
| Ondansetron Hcl | Ondansetron Hcl | 121 | 55 |
| Fluoxetine Hcl | Fluoxetine Hcl | 120 | 29 |
| Bupropion Xl | Bupropion Hcl | 119 | 24 |
| Bumetanide | Bumetanide | 117 | 24 |
| Torsemide | Torsemide | 115 | 21 |
| Colchicine | Colchicine | 114 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 106 | 27 |
| Baclofen | Baclofen | 102 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 27 |
| Alendronate Sodium | Alendronate Sodium | 99 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 99 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 21 |
| Montelukast Sodium | Montelukast Sodium | 98 | 24 |
| Meloxicam | Meloxicam | 96 | 22 |
| Ozempic | Semaglutide | 96 | 19 |
| Atenolol | Atenolol | 94 | 17 |
| Pregabalin | Pregabalin | 94 | 18 |
| Tradjenta | Linagliptin | 94 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 93 | 16 |
| Metformin Hcl Er | Metformin Hcl | 91 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 91 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 56 |
| Cefuroxime | Cefuroxime Axetil | 88 | 68 |
| Topiramate | Topiramate | 88 | suppressed |
| Chlorthalidone | Chlorthalidone | 83 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 74 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 73 | 54 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 30 |
| Movantik | Naloxegol Oxalate | 69 | suppressed |
| Olanzapine | Olanzapine | 68 | 17 |
| Synthroid | Levothyroxine Sodium | 68 | 18 |
| Ibuprofen | Ibuprofen | 67 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 23 |
| Meclizine Hcl | Meclizine Hcl | 66 | 21 |
| Primidone | Primidone | 66 | suppressed |
| Cephalexin | Cephalexin | 64 | 34 |
| Methocarbamol | Methocarbamol | 63 | 25 |
| Metoclopramide Hcl | Metoclopramide Hcl | 63 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 61 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 13 |
| Glimepiride | Glimepiride | 60 | 18 |
| Irbesartan | Irbesartan | 60 | 16 |
| Entresto | Sacubitril/Valsartan | 58 | suppressed |
| Novolog Flexpen | Insulin Aspart | 56 | 18 |
| Brimonidine Tartrate | Brimonidine Tartrate | 55 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 55 | 11 |
| Celecoxib | Celecoxib | 54 | 15 |
| Morphine Sulfate | Morphine Sulfate | 54 | 49 |
| Sucralfate | Sucralfate | 54 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 53 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 53 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 19 |
| Divalproex Sodium Er | Divalproex Sodium | 52 | suppressed |
| Januvia | Sitagliptin Phosphate | 52 | 12 |
| Klor-Con M15 | Potassium Chloride | 52 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 52 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 51 | 15 |
| Lactulose | Lactulose | 51 | 27 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 51 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 50 | 18 |
| Nystatin | Nystatin | 50 | 30 |
| Hydrocortisone | Hydrocortisone | 48 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 11 |
| Azithromycin | Azithromycin | 45 | 42 |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | 11 |
| Glipizide | Glipizide | 45 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 45 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 13 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 42 | 41 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 13 |
| Letrozole | Letrozole | 40 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 29 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 39 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | suppressed |
| Nyamyc | Nystatin | 39 | 23 |
| Anastrozole | Anastrozole | 38 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 37 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 11 |
| Hydroxyurea | Hydroxyurea | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 31 |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 32 |
| Risperidone | Risperidone | 33 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 19 |
| Nitroglycerin | Nitroglycerin | 32 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 30 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 30 | 19 |
| Lubiprostone | Lubiprostone | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Sotalol | Sotalol Hcl | 29 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Humalog | Insulin Lispro | 28 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Timolol Maleate | Timolol Maleate | 27 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 26 | 20 |
| Gemtesa | Vibegron | 26 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Otezla | Apremilast | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Trimethoprim | Trimethoprim | 25 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 24 | 20 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 16 |
| Fluconazole | Fluconazole | 24 | 18 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 19 |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 16 |
| Lagevrio (Eua) | Molnupiravir | 22 | 20 |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Leflunomide | Leflunomide | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Calcium Acetate | Calcium Acetate | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Permethrin | Permethrin | 20 | 14 |
| Santyl | Collagenase Clostridium Hist. | 20 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Procto-Med Hc | Hydrocortisone | 19 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 18 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 13 |
| Mometasone Furoate | Mometasone Furoate | 18 | 11 |
| Nuplazid | Pimavanserin Tartrate | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 17 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 17 | 14 |
| Lidocaine | Lidocaine | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Ertapenem | Ertapenem Sodium | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 16 |
| Restasis | Cyclosporine | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | 11 |
| Combigan | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Glucagon Emergency Kit | Glucagon | 13 | 11 |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Tirosint | Levothyroxine Sodium | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Risperidone Er | Risperidone Microspheres | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $408.19 · 21 records | Novo Nordisk Inc | AIRSUPRA, CAPLYTA, CAPVAXIVE, ELIQUIS, GEMTESA, INCEPTIV, NUPLAZID, NURTEC ODT, OTEZLA, Omnipod, Ozempic, REPATHA, REXULTI, Rybelsus, SPRAVATO, VELSIPITY, VOQUEZNA, Wegovy, XIFAXAN | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error